Zubair Khan, MD
Interventional Cardiology · Las Vegas, NVNPI 1720417793
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.8%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Boston Scientific at 32.6% of the total. 2025 is the largest year on record at $7,053, 6.3 times the $1,127 reported in 2019.
Across 358 payments — averaging $43.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$5K
- Medtronic$3K
- Abbott$3K
- Johnson & Johnson$1K
- Novartis$836
- Abiomed$701
- plus $3K from 29 others
What the payments were for
- Consulting fees$3,12520%
- Travel & lodging$4,56829%
- Food & beverage$7,99051%
- Education$420%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 11 | $5,120 |
| Medtronic | 29 | $2,880 |
| Abbott | 42 | $2,539 |
| Johnson & Johnson | 61 | $1,016 |
| Novartis | 51 | $836 |
| Abiomed | 12 | $701 |
| Pfizer | 23 | $346 |
| AstraZeneca | 18 | $331 |
| Merck | 15 | $293 |
| Amgen | 21 | $272 |
| Shockwave Medical, Inc | 6 | $216 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $183 |
| Sanofi-aventis U.S. LLC | 9 | $144 |
| Esperion Therapeutics, Inc. | 5 | $83 |
| Novo Nordisk | 4 | $78 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $72 |
| E.r. Squibb & Sons, L.L.C. | 4 | $71 |
| Actelion Pharmaceuticals US, Inc. | 6 | $69 |
| Boehringer Ingelheim | 3 | $56 |
| Smith+Nephew | 2 | $45 |
| United Therapeutics Corporation | 2 | $36 |
| Amarin Pharma, Inc. | 2 | $33 |
| Bayer | 2 | $33 |
| Tactile Systems Technology Inc | 2 | $32 |
| Baxter Healthcare | 2 | $29 |
| Irhythm Technologies, Inc. | 2 | $26 |
| Bridgebio Pharma, Inc. | 1 | $25 |
| Galderma Laboratories, L.p. | 1 | $24 |
| Nuwellis, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $22 |
| Cardiovascular Systems Inc. | 1 | $21 |
| Edwards Lifesciences | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| Chiesi USA, Inc. | 1 | $15 |
| Philips North America LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vitalyst$4,778
- Micra$1,121
- PERCLOSE PROGLIDE$1,076
- ONYX FRONTIER$772
- FFRangio$174
- GENERAL ULTRASOUND$174
- SYMPLICITY G3$167
- CROSSBOSS$140
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$134
- Perclose ProStyle$125
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$120
- ACCENT$109
- ESPRIT$100
How this compares
$15,725 in reported general payments places this provider in the 70th percentile of 62 interventional cardiology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 368 | $353,397 |
| XareltoRivaroxaban | 150 | $146,246 |
| EntrestoSacubitril/Valsartan | 104 | $121,132 |
| FarxigaDapagliflozin Propanediol | 131 | $113,479 |
| MultaqDronedarone Hcl | 41 | $43,828 |
| BrilintaTicagrelor | 58 | $35,876 |
| Repatha SureclickEvolocumab | 40 | $31,762 |
| VascepaIcosapent Ethyl | 33 | $14,431 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 12 | $13,084 |
| Ranolazine ErRanolazine | 120 | $10,297 |
| Atorvastatin Calcium | 618 | $8,648 |
| Metoprolol Succinate | 482 | $6,932 |
| Ezetimibe | 258 | $6,823 |
| Dofetilide | 23 | $6,381 |
| TrintellixVortioxetine Hydrobromide | 11 | $5,752 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $346 | $353,397368 claims |
| AstraZenecaFarxiga, Brilinta | $331 | $149,354189 claims |
| Johnson & JohnsonXarelto | $1,016 | $146,246150 claims |
| NovartisEntresto | $836 | $121,132104 claims |
| Sanofi-aventis U.S. LLCMultaq | $144 | $43,82841 claims |
| Boehringer IngelheimSynjardy Xr | $56 | $13,08412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 62 interventional cardiology providers in Nevada.
Other interventional cardiology in Las Vegas
- Cres MirandaLas Vegas$660K
- Adrian Mercado-AlamoLas Vegas$118K
- Nayab ZafarLas Vegas$102K
- William ChuLas Vegas$75K
- Neville MistryLas Vegas$36K
- Leon VarjabedianLas Vegas$34K
- Moniz DawoodLas Vegas$29K
- Andrew LuxhojLas Vegas$22K
- Mohi AlkadriLas Vegas$20K
- John BedottoLas Vegas$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.